Teva and Celltrion Launch Herzuma (biosimilar- trastuzumab) in the US
Teva, Celltrion Partner | Technology Networks
FiercePharmaAsia—China's new drug regulator, Teva's Celltrion headache, NextCODE-Google tie-up | Fierce Pharma
New data raise profile of Truxima at EHA 2021
Teva, Celltrion launch Herceptin biosimilar in US - Globes
Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International
Celltrion presents Truxima's results of phase 3 clinical trials in US forum
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion | Pharmafile
Teva teams with Celltrion in $160m biosimilar deal - Globes
Celltrion, Teva announce FDA approval of HERZUMA
Celltrion launches Herceptin biosimilar in US
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Teva and Celltrion Launch Rituximab Biosimilar in US - Big Molecule Watch
Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Celltrion riding high on biosimilars - Nikkei Asia
Teva confident in September approval for migraine drug despite latest Celltrion plant citation | Fierce Pharma
Celltrion Completes Resubmission for Biosimilar Candidate to FDA for Review | Business Wire
Biosimilars: Celltrion paves way for Herceptin copycats in 2018 - Pharmaceutical Technology
Amgen and Allergan's Kanjinti (trastuzumab-anns) Biosimilar Product Profile
